I am going to be tracking changes in methylation status of cells over time and with varying treatments. For MBD seq do I need to sequence a corresponding input reaction for every time point and treatment or can I compare the different groups to each other instead? I will be analyzing untreated time point one as a baseline. Would this suffice?
-
-
In general when we're doing this type of enrichment work we only do a single input sample using the same conditions as for the enriched samples. Most of the artefacts come from the DNA preparation, mapping and sequencing stages and won't change between timepoints or treatments (unless you have a treatment which is going to grossly change the structure of your DNA in some way). Doing a matched input for each sample would get really expensive really quickly!
In some cases we don't bother doing an input at all but just use data from previous inputs we've run to either use in the analysis or to provide sets of regions which we should ignore.
-
Tumors contain complex mixtures of cell populations that evolve in response to treatment and host-specific factors. Tissue biopsies provide only static snapshots of a tumor’s state. But what if we could follow that evolution over time using a minimally invasive technique?
Liquid biopsies can detect tumor-derived material circulating in the bloodstream, providing a way to study treatment response, detect emerging resistance, and discover new biomarkers. Circulating...10-14-2026, 09:55 AM -
Researchers using sequencing and genomics tools often have to make trade-offs. They can choose between speed or scale, short reads or long-range information, or targeted panels or a view of the whole transcriptome. New technologies that have been released this year are built to address those tough choices.
We asked six companies the same four questions to learn about their latest products. The new technologies bring a lot to the table, including rethinking sequencing...
Comment